What is NBIX's P/E ratio?

Neurocrine Biosciences Inc (NBIX) currently trades at a P/E ratio of 26.44.

Neurocrine Biosciences Inc reports a Return on Equity (ROE) of 17.68%.

What is NBIX's dividend yield?

Neurocrine Biosciences Inc offers a dividend yield of 0.00%.

What is NBIX's Quality Score?

Our AI rates NBIX's overall financial quality at 100 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NBIX?

Our AI Timing Score for NBIX is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NBIX belong to?

Neurocrine Biosciences Inc is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

Neurocrine Biosciences Inc (NBIX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

NBIX AI Analysis Summary

Our AI summary for NBIX: Neurocrine Biosciences Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 26.44, ROE of 17.68%, a dividend yield of 0.00%. Its financial Quality Score stands at 100/100 — fundamentals stronger than most of the market. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

NBIX

Neurocrine Biosciences Inc

USD 166.80

-18.70 (-10.08%) Day Change

Watchlist Portfolio Compare Chart

26.44

P/E

0.34

D/E

17.7%

ROE

13.2%

ROA

0.00%

Div Yield

0.60

PEG

NEUROCRINE BIOSCIENCES INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 166.80 Price -18.70 (-10.08%) Day Change	NEWS SCORE: 99

NBIX, the overall quality is excellent ( Quality = 100) and the timing to buy is ...(Sign In to See)...

Loading chart...

100 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Excellent

Reason: Company financial health is Excellent from almost all quality indicators

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...

Quality Factors

54%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.12 From 30 days period
News Score	99
Magic Formula Rank by ROA	1135
Magic Formula Rank by ROE	1135
Magic Formula Rank by ROIC	1063
Price	166.80
PBV / Sector	4.67 / 3.22
Earning Per Share	6.31

PE / Sector	26.44 / 29.79
PEG or PE/Growth / Sector	0.60 / 0.13 GOOD
Average 1M Daily Value	228.74 M GREAT
Average 1W Daily Value	357.39 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

58%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

72%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	20.91 / 15.21 GREAT
NPM Average (%) / Sector	15.15 / -10.83 GREAT
NPM Change Average (%) / Sector	19.36 / 117.42 GOOD
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	13.16 / 8.15
ROA Average (%) / Sector	9.38 / 2.87
ROA Change Average (%) / Sector	19.31 / 112.70 GOOD
ROE (%) / Sector	17.68 / -1.02
ROE Average (%) / Sector	13.16 / 8.35
ROE Change Average (%) / Sector	18.31 / 385.91 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 08:00:13
Symbol	NBIX
Name	NEUROCRINE BIOSCIENCES INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	100.55 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	18,652.02 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 6027 Edgewood Bend Court, San Diego, CA, United States, 92130

Phone: 858 617 7600

Website: https://www.neurocrine.com

Employees: 2,000

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.